JP2004526778A - 脂肪族ポリアミンを用いるｘ症候群の処置方法 - Google Patents

脂肪族ポリアミンを用いるｘ症候群の処置方法 Download PDF

Info

Publication number
JP2004526778A
JP2004526778A JP2002582955A JP2002582955A JP2004526778A JP 2004526778 A JP2004526778 A JP 2004526778A JP 2002582955 A JP2002582955 A JP 2002582955A JP 2002582955 A JP2002582955 A JP 2002582955A JP 2004526778 A JP2004526778 A JP 2004526778A
Authority
JP
Japan
Prior art keywords
salt
polymer
syndrome
administered
alkyl halide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002582955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004526778A5 (https=
Inventor
バーク，スティーブン，ケイ．
ドノバン，ジョアン，エム．
Original Assignee
ジェンザイム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンザイム コーポレーション filed Critical ジェンザイム コーポレーション
Publication of JP2004526778A publication Critical patent/JP2004526778A/ja
Publication of JP2004526778A5 publication Critical patent/JP2004526778A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002582955A 2001-04-18 2002-04-10 脂肪族ポリアミンを用いるｘ症候群の処置方法 Withdrawn JP2004526778A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US35591702P 2002-02-11 2002-02-11
PCT/US2002/011495 WO2002085382A1 (en) 2001-04-18 2002-04-10 Methods of treating syndrome x with aliphatic polyamines

Publications (2)

Publication Number Publication Date
JP2004526778A true JP2004526778A (ja) 2004-09-02
JP2004526778A5 JP2004526778A5 (https=) 2005-12-22

Family

ID=26962627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582955A Withdrawn JP2004526778A (ja) 2001-04-18 2002-04-10 脂肪族ポリアミンを用いるｘ症候群の処置方法

Country Status (11)

Country Link
US (2) US7261880B2 (https=)
EP (2) EP1379259A1 (https=)
JP (1) JP2004526778A (https=)
KR (1) KR20040018359A (https=)
CN (1) CN1509180A (https=)
AU (1) AU2002257147B9 (https=)
BR (1) BR0209124A (https=)
CA (1) CA2444028A1 (https=)
MX (1) MXPA03009562A (https=)
WO (1) WO2002085382A1 (https=)
ZA (1) ZA200308066B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020116555A (ja) * 2019-01-28 2020-08-06 久保田　徹 機能水

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
EP1379259A1 (en) * 2001-04-18 2004-01-14 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP3000460A1 (en) 2005-09-15 2016-03-30 Genzyme Corporation Sachet formulation for amine polymers
EP2016114A2 (en) * 2006-05-05 2009-01-21 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
AU2007275711A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US8163799B2 (en) * 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
JP2010519298A (ja) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
EP2131820A1 (en) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
WO2009078958A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Coated pharmaceutical compositions
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
EP2361171A4 (en) * 2008-09-15 2014-11-05 Shasun Chemicals And Drugs Ltd PROCESS FOR PREPARING NETWORKED POLYMERS IN A NON-AQUEOUS SOLUTION
WO2011106542A2 (en) 2010-02-24 2011-09-01 Relypsa, Inc. Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants
US9475891B2 (en) * 2013-09-19 2016-10-25 Navinta, Llc Process for the preparation of colesevelam hydrochloride
BR112019013364A2 (pt) 2016-12-28 2020-04-14 Fujifilm Corp emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505851A (ja) * 1990-12-07 1993-08-26 インペリアル　ケミカル　インダストリーズ　ピーエルシー 窒素誘導体
JPH09500368A (ja) * 1993-06-02 1997-01-14 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 胆汁酸塩を除去するための組成物および方法
JPH10501264A (ja) * 1994-06-10 1998-02-03 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 患者から胆汁酸塩を除去するための架橋ポリマー
JPH10501842A (ja) * 1994-06-10 1998-02-17 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 患者から胆汁酸塩を除去する方法およびそのためのアルキル化組成物
WO1998057652A1 (en) * 1997-06-18 1998-12-23 Geltex Pharmaceuticals, Inc. Polyallylamine polymers for treating hypercholesterolemia
JPH11507093A (ja) * 1995-06-06 1999-06-22 ジェルテックス ファーマシューティカルズ，インコーポレイテッド コレステロール減少用疎水性ヘテロ原子含有金属イオン封鎖剤
WO1999034787A2 (en) * 1998-01-09 1999-07-15 Geltex Pharmaceuticals, Inc. Fat-binding polymers
WO2000038728A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
WO2000038723A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IE914179A1 (en) * 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5468727A (en) 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
BR9306040A (pt) 1992-03-06 1997-11-18 Statens Seruminstitut Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5929184A (en) 1993-06-02 1999-07-27 Geltex Pharmaceuticals, Inc. Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US6129910A (en) * 1993-06-02 2000-10-10 Geltex Pharmaceuticals, Inc. Water-insoluble noncrosslinked bile acid sequestrants
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1996021454A1 (en) * 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US6034129A (en) 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
US6290947B1 (en) 1997-09-19 2001-09-18 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin-binding agents
US6007803A (en) 1997-09-19 1999-12-28 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin binding agents
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
WO2000001679A1 (en) * 1998-07-01 2000-01-13 Takeda Chemical Industries, Ltd. Retinoid-associated receptor regulators
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6190649B1 (en) 1999-04-23 2001-02-20 Geltex Pharmaceuticals, Inc. Polyether-based bile acid sequestrants
AU4803800A (en) 1999-04-27 2000-11-10 Trustees Of The University Of Pennsylvania, The Compositions, methods, and kits relating to LTiGTresistinLT/iGT
JP2004500332A (ja) 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
WO2001025291A1 (en) 1999-10-07 2001-04-12 University Of Maryland Sugar binding polymers and the use thereof
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1379259A1 (en) * 2001-04-18 2004-01-14 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
US20020198202A1 (en) 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505851A (ja) * 1990-12-07 1993-08-26 インペリアル　ケミカル　インダストリーズ　ピーエルシー 窒素誘導体
JPH09500368A (ja) * 1993-06-02 1997-01-14 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 胆汁酸塩を除去するための組成物および方法
JPH10501264A (ja) * 1994-06-10 1998-02-03 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 患者から胆汁酸塩を除去するための架橋ポリマー
JPH10501842A (ja) * 1994-06-10 1998-02-17 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 患者から胆汁酸塩を除去する方法およびそのためのアルキル化組成物
JPH11507093A (ja) * 1995-06-06 1999-06-22 ジェルテックス ファーマシューティカルズ，インコーポレイテッド コレステロール減少用疎水性ヘテロ原子含有金属イオン封鎖剤
WO1998057652A1 (en) * 1997-06-18 1998-12-23 Geltex Pharmaceuticals, Inc. Polyallylamine polymers for treating hypercholesterolemia
WO1999034787A2 (en) * 1998-01-09 1999-07-15 Geltex Pharmaceuticals, Inc. Fat-binding polymers
WO2000038728A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
WO2000038723A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
G. M. CHERTOW ET AL.: "Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 14, no. 12, JPN6008063060, December 1999 (1999-12-01), pages 2907 - 2914, XP008049272, ISSN: 0001202385, DOI: 10.1093/ndt/14.12.2907 *
H. H. KNAPP ET AL.: "Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholest", AMERICAN JOURNAL OF MEDICINE, vol. 110, no. 5, JPN6008063055, 1 April 2001 (2001-04-01), pages 352 - 360, ISSN: 0001202383 *
M. H. DAVIDSON ET AL.: "Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low i", ARCHIVES OF INTERNAL MEDICINE, vol. 159, no. 16, JPN6008063058, 13 September 1999 (1999-09-13), pages 1893 - 1900, ISSN: 0001202384 *
S. K. BURKE ET AL.: "RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in norm", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 12, no. 8, JPN6008063061, August 1997 (1997-08-01), pages 1640 - 1644, ISSN: 0001202386 *
WONG N N ET AL.: "Colesevelam: a new bile acid sequestrant.", HEART DISEASE, vol. 3, no. 1, JPN6010040052, February 2001 (2001-02-01), pages 63 - 70, XP009003564, ISSN: 0001674710, DOI: 10.1097/00132580-200101000-00009 *
中谷矩章: "陰イオン交換樹脂", 日本臨牀 高脂血症（下巻）, vol. Vol. 59, 増刊号3, (通巻788号), JPN6010040055, 31 March 2001 (2001-03-31), pages 642 - 649, ISSN: 0001674714 *
向井田英明 他: "肥満とsyndrome X", 日本臨牀, vol. Vol. 53, 1995年特別号, JPN6010040053, 22 June 1995 (1995-06-22), pages 577 - 581, ISSN: 0001674711 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020116555A (ja) * 2019-01-28 2020-08-06 久保田　徹 機能水
WO2020158632A1 (ja) * 2019-01-28 2020-08-06 久保田　徹 機能水

Also Published As

Publication number Publication date
KR20040018359A (ko) 2004-03-03
BR0209124A (pt) 2005-02-09
EP1379259A1 (en) 2004-01-14
WO2002085382A1 (en) 2002-10-31
US20030049226A1 (en) 2003-03-13
US20080085872A1 (en) 2008-04-10
US7261880B2 (en) 2007-08-28
CN1509180A (zh) 2004-06-30
CA2444028A1 (en) 2002-10-31
ZA200308066B (en) 2005-03-30
EP2172204A1 (en) 2010-04-07
MXPA03009562A (es) 2004-02-12
AU2002257147B2 (en) 2005-07-14
AU2002257147B9 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
JP2004526778A (ja) 脂肪族ポリアミンを用いるｘ症候群の処置方法
AU2002257147A1 (en) Methods of treating Syndrome X with aliphatic polyamines
JP4499363B2 (ja) 血清グルコースの減少方法
JP4420143B2 (ja) 高コレステロール血症を治療するためのポリアリルアミンポリマー
JP5922184B2 (ja) アミンポリマー用サシェ製剤
DK1807057T3 (en) ALIFATIC AMINE POLYMER SALTS FOR TABLET PREPARATION
AU2001289699B2 (en) New pharmaceutical composition
US20090304623A1 (en) Once A Day Formulation for Phosphate Binders
US20080112918A1 (en) Method for treating gout and binding uric acid
US20020187120A1 (en) Method for treating gout and reducing serum uric acid
ZA200308063B (en) Method of lowering serum glucose.
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
EP1923064B1 (en) Use of amine polymer for lowering serum glucose
HK1029920B (en) Polyallylamine polymers for treating hypercholesterolemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090331

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101001

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110318

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110509